# US 2001/0034353 A1 · Methods for reducing non-inflammatory pain

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0034353 A1
- Document ID: US20010034353A1
- Status: Published application
- Kind: A1
- Application number: 09/838,772
- Filed: 2001-04-19
- Published: 2001-10-25
- Earliest claimed: 1999-07-30
- Assignees: Allergan Sales, Inc.
- Inventors: Janet K. Cheetham; Harold G. Jensen; Christopher A. Muller; David F. Power; Kevin D. Skule
- Web page: https://patentgrep.com/patent/US20010034353A1

## CPC

- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 31/196: the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A61K 31/535: having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K 31/5365: ortho- or peri-condensed with heterocyclic ring systems
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods for reducing non-inflammatory pain caused by injuries and traumas include administering to a mammal eye having non-inflammatory pain a therapeutically effective amount of a composition comprising a quinolone component in an amount effective as an antibiotic and a NSAID component in an amount effective, in combination with the quinolone component, to provide a reduction in non-inflammatory pain.

## Claims

### Claim 1

A method for reducing the pain caused by a corneal injury comprising:
administering to a mammalian eye having a corneal injury a therapeutically effective amount of a composition comprising a quinolone component in an amount effective as an antibiotic in the mammalian eye and a NSAID component in an amount effective, in combination with the quinolone component, to provide a reduction in non-inflammatory pain caused by the corneal injury.

### Claim 2 (depends on 1)

The method of claim 1 wherein the NSAID component is present in an amount effective, in combination with the quinolone component, to provide a reduction in both non-inflammatory pain and inflammatory pain caused by the corneal injury.

### Claim 3 (depends on 1)

The method of claim 1 wherein the corneal injury is a corneal ulcer.

### Claim 4 (depends on 1)

The method of claim 1 herein the quinolone component is a halogenated quinolone component.

### Claim 5 (depends on 1)

The method of claim 1 wherein the quinolone component is a fluorinated quinolone component.

### Claim 6 (depends on 1)

The method of claim 1 wherein the quinolone component is an ofloxacin component

### Claim 7 (depends on 6)

The method of claim 6 wherein the corneal injury is a corneal ulcer.

### Claim 8 (depends on 1)

The method of claim 1 wherein the NSAID component is a carboxyl group-containing NSAID component.

### Claim 9 (depends on 1)

The method of claim 1 wherein the NSAID component is a ketorolac component.

### Claim 10 (depends on 9)

The method of claim 9 wherein the corneal injury is a corneal ulcer.

### Claim 11 (depends on 1)

The method of claim 1 wherein the NSAID component is a ketorolac component.

### Claim 12 (depends on 11)

The method of claim 11 wherein the corneal injury is a corneal ulcer.

### Claim 13

A method for reducing pain comprising:
administering to a mammal having non-inflammatory pain a therapeutically effective amount of a composition comprising a quinolone component in an amount effective as an antibiotic and a NSAID component in an amount effective, in combination with the quinolone component, to provide a reduction in the non-inflammatory pain.

### Claim 14 (depends on 13)

The method of claim 13 wherein the mammal has inflammatory pain and the NSAID component is present in an amount effective, in combination with the quinolone component to provide a reduction in both non-inflammatory pain and inflammatory pain.

### Claim 15 (depends on 13)

The method of claim 13 wherein the mammal has non-inflammatory pain caused by an ocular injury.

### Claim 16 (depends on 13)

The method of claim 13 herein the quinolone component is a halogenated quinolone component.

### Claim 17 (depends on 13)

The method of claim 13 wherein the quinolone component is a fluorinated quinolone component.

### Claim 18 (depends on 13)

The method of claim 13 wherein the quinolone component is an ofloxacin component

### Claim 19 (depends on 18)

The method of claim 18 wherein the mammal has non-inflammatory pain and inflammatory pain caused by an ocular injury, and the NSAID component is present in an amount effective, in combination with the quinolone component to provide a reduction in both non-inflammatory pain and inflammatory pain.

### Claim 20 (depends on 13)

The method of claim 13 wherein the NSAID component is a carboxyl group-containing NSAID component.

### Claim 21 (depends on 13)

The method of claim 13 wherein the NSAID component is a ketorolac component.

### Claim 22 (depends on 21)

The method of claim 21 wherein the mammal has non-inflammatory pain and inflammatory pain caused by an ocular injury, and the NSAID component is present in an amount effective, in combination with the quinolone component to provide a reduction in both non-inflammatory pain and inflammatory pain.

### Claim 23 (depends on 13)

The method of claim 13 wherein the NSAID component is a ketorolac component.

### Claim 24 (depends on 23)

The method of claim 23 wherein the mammal has non-inflammatory pain and inflammatory pain caused by an ocular injury, and the NSAID component is present in an amount effective, in combination with the quinolone component to provide a reduction in both non-inflammatory pain and inflammatory pain.
